Bristol Touts Opdivo's Stability – And Diversity – In Strong Q2

The recently launched Opdivo/Yervoy combination already has a leading position in first-line kidney cancer in the US – with a 30% share of new patients – but has been rejected in Europe.

Business concept illustrations of diversification. Golden eggs in different baskets. Vector diversification business, golden eggs in basket

Beating expectations for the second quarter, Bristol-Myers Squibb Co. touted the stability of its PD-1 inhibitor Opdivo in second-line metastatic non-small cell lung cancer (NSCLC), as well as the diversity of the immuno-oncology franchise overall, especially strong performance of the Opdivo/Yervoy combo in renal cancer.

More from Earnings

Stock Watch: Are Gene Therapy Prices Too High For Success?

 
• By 

The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.

Crunch Time Close For Abivax’s IBD Ambitions

 
• By 

Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.

Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Stock Watch: Hesitant Vaccine Sales For CSL Reflect Wider Issues

 
• By 

CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.

More from Business

Can New US FDA Commissioner Makary Calm Agency During Turbulent Times?

 

Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.

Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq

 
• By 

Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By 

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.